Small molecules that block bacterial toxin formation have shown promise against Gram-positive bacteria in mouse models.
Browsing: Drug Development
In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.
GARDP and Novartis have announced a partnership hoping to accelerate the development and availability of generic antibiotics for children in LMICs.
Researchers from Genentech have carried out optimization of the arylomycins, uncovering a molecule with potent, broad-spectrum activity against Gram-negative bacteria.
A team of researchers from Imperial College London (UK) have identified compounds which prevent the malarial parasite sexually maturing inside the mosquito.
Scientists at the University of Manchester (UK) have developed the first non-antibiotic drug to successfully…
Financial modelling has been used to estimate the costs and likelihood of candidate medicines, vaccines, diagnostics and technologies launching, revealing gaps in the pipeline and in funding.
From antibiotic susceptibility testing to new instruments to screen for antibiotics, 3D printing is contributing to research on antimicrobial resistance.
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.